Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $44.83.

Several research analysts recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating on shares of Omnicell in a research note on Friday, May 23rd. Wells Fargo & Company restated an “overweight” rating and issued a $37.00 price objective (up previously from $35.00) on shares of Omnicell in a report on Friday, May 23rd. JPMorgan Chase & Co. decreased their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, March 20th. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 12th. Finally, Bank of America upped their price target on Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, May 23rd.

Omnicell Stock Up 2.0%

OMCL stock opened at $27.78 on Thursday. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.75. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of 60.39, a price-to-earnings-growth ratio of 8.17 and a beta of 0.76. The business’s 50 day moving average price is $29.02 and its two-hundred day moving average price is $34.41. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.38.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to analysts’ expectations of $260.18 million. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 earnings per share. As a group, analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMCL. Vanguard Group Inc. grew its stake in shares of Omnicell by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after acquiring an additional 28,573 shares during the period. Victory Capital Management Inc. boosted its holdings in Omnicell by 10.1% in the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company’s stock worth $58,745,000 after purchasing an additional 154,038 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after purchasing an additional 394,820 shares during the period. Lazard Asset Management LLC raised its stake in Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock valued at $73,093,000 after buying an additional 737,536 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in shares of Omnicell by 4.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company’s stock valued at $53,290,000 after buying an additional 56,117 shares during the period. 97.70% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.